NEW YORK, NY -- (Marketwire) -- 12/12/12 -- Oculus Innovative Sciences, Inc (NASDAQ: OCLS) announced several key factors that will drive its expected EBITAS profitability in FY2014 including possible partnerships in Europe, increased revenue and reduction of SG&A costs as a result of their partnership with More Pharma.
Oculus, a healthcare company that designs, produces and markets innovative and safe anti-infective medical devices and treatments for acne. The Company's Microcyn® Technology Platform is capable of producing a pH-neutral, non-irritating solution of oxychlorine compounds that are similar to the chemicals produced by the human body in its defense against microorganisms. Visiongain, an independent business information provider estimates that wound care products are expected to rise over the next 10 years driven by an increase of chronic wounds in an aging population. Visiongain expects the wound care market to top $16 billion by 2023.
For more information on Oculus, please visit www.oculusis.com
This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid IO Circuit one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.